Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS)

No abstract is available for this paper.

• Publication year

  2016

• Venue

  British Journal of Haematology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.14345PMID 27714772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.

  2016cited by this paper
• A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

  2015cited by this paper
• A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

  2015cited by this paper
• Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation.

  2013cited by this paper
• Mammalian target of rapamycin inhibitor-associated stomatitis.

  2013cited by this paper
• Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107)

  2012cited by this paper
• A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

  2011cited by this paper
• Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality?

  2011cited by this paper
• IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

  2009cited by this paper
• Differential Responses of Human Regulatory T Cells (Treg) and Effector T Cells to Rapamycin

  2009cited by this paper
• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

  2007cited by this paper
• Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

  2007cited by this paper
• The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

  2006cited by this paper
• Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1

  2006cited by this paper
• Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

  2006cited by this paper
• Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

  2006cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study

  2005cited by this paper
• Antileukemic activity of rapamycin in acute myeloid leukemia.

  2005cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Blood Levels of Angiogenin and Vascular Endothelial Growth Factor Are Elevated in Myelodysplastic Syndromes and in Acute Myeloid Leukemia

  2002cited by this paper
• Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.

  2001cited by this paper
• A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

  2001cited by this paper
• Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

  2001cited by this paper
• Angiogenesis in myelodysplastic syndromes

  1999cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• [Phase III study].

  1995cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes

  2022cites this paper
• Inflammation and myeloid malignancy: Quenching the flame.

  2022cites this paper
• The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside

  2021cites this paper
• Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity

  2019cites this paper
• Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.

  2019cites this paper
• Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

  2018cites this paper
• Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML

  2018cites this paper
• Drugs that Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs

  2015cites this paper